

# Topical Collection

## Targeted Cancer Therapy

### Message from the Collection Editor

Targeted therapy is one of the major cancer treatment methods available today. The identification of tumor-specific drug targets allows precise targeting of cancer cells while minimizing damage to healthy tissues. Comprehensive genomic characterization of tumor types has helped to advance the development of novel therapies for precision oncology. However, the identification of novel druggable targets, relevant mechanisms, and effective combination therapies is needed. The development of resistance through intrinsic and acquired genomic alterations and signaling to targeted therapy, resulting in exceptional responses lasting for only a short duration, is still a major issue. Furthermore, the success of novel therapies may be hindered by adverse side effects. The objective of the current Topical Collection in *Cancers* is to publish original research papers and reviews from authors who are interested in addressing these challenges and provide new insights and novel treatment strategies for targeted cancer therapies.

---

### Collection Editor

Dr. Jason Roszik

Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

---



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/109713](https://mdpi.com/si/109713)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)